There is one clinical trial.
Brazil was the first middle-income country to provide free and universal access to antiretroviral drugs to HIV infected individuals. Since 2014 local guidelines recommend that all HIV infected individuals be started on therapy regardless of CD4 count. Since January 2017, all patients are started on a DTG containing triple regimen. As of November 2018, 170,000 individuals were receiving DTG through the public health system. It is a public health priority to evaluate the risk of virologic failure and the subsequent development of INSTI resistance in these real-life settings. Our preliminary data from Brazil indicated a high virologic failure rate of 8% after 18 months of treatment TL+D. Our central hypothesis is that TDR may be associated and contribute to virologic failure with DTG in clinical practice. To test this central hypothesis, we will identify PLWH failing DTG containing regimens in Brazil. The insights generated with these studies will contribute to a more effective use of second generation INSTI in the future.
The prevalence of the polymorphic IN mutations L101I and T124A, which are in vitro pathway for resistance, were 53.5% and 46.4%, respectively, significantly higher than in Brazilian INSTI naïve patients. --- L101I --- --- T124A ---
Description: Viral load in patient trated with first line treatment withTenofovir/3TC + DolutegravirMeasure: HIV RNA Viral Load Time: 24 weeks
Description: HIV reverse transcriptase resistance test in virologic failure patientMeasure: HIV transcriptase resitance mutations Time: 24 weeks
Description: HIV transcriptase resistance test in virologic failure patientMeasure: HIV integrase resitance mutations Time: 24 weeks